WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory
GlaxoSmithKline GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.

www.gsk.com

List of articles in category GlaxoSmithKline
Title Published Date
GlaxoSmithKline announces start of two phase III studies in advanced/metastatic melanoma 24 January 2011
GlaxoSmithKline announces Q4 2010 legal charge 17 January 2011
GlaxoSmithKline and ChemoCentryx announce initiation of Phase III study of GSK'786 13 January 2011
GSK responds to 60 Minutes | Related Video 03 January 2011
GSK to acquire Nanjing MeiRui Pharmaceuticals in China 09 December 2010
GlaxoSmithKline to increase its shareholding in Theravance 29 November 2010
GlaxoSmithKline and JSC Binnopharm enter vaccine production alliance in Russia 28 November 2010
GlaxoSmithKline receives approval in Japan for two medicines: Revolade and Xyzal 31 October 2010
GSK outlines approach to delivering advances in the treatment of rare diseases 19 October 2010
GSK increases support for WHO strategy to improve children's health 18 October 2010
  • Start
  • Prev
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • Next
  • End
Tahmeena

Business & Industry

  • Pfizer reports record full-year 2022 results
  • AMJEVITA™ (adalimumab-atto), first biosimilar to Humira® now available in the United States
  • CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer
  • Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
  • Pfizer expands 'An Accord for a Healthier World' product offering to include full portfolio for greater benefit to 1.2 billion people in 45 lower-income countries

Research & Development

  • Scientists pinpoint protein that helps cancer-causing viruses evade immune response
  • Transforming the way cancer vaccines are designed and made
  • Antidepressants used for chronic pain on the rise, but are they effective?
  • Keys to making immunotherapy work against pancreatic cancer found in tumor microenvironment
  • Discovery of anti-cancer chemistry makes skullcap fit for modern medicine
  • Coordination of COVID-19 vaccine clinical trials produces a 'treasure trove' of data and a model for the future
  • Power of cancer drugs may see boost by targeting newly ID'd pathway

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  • FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
  1. You are here:  
  2. Home
  3. GlaxoSmithKline
  4. SK bioscience and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.